Syntex ganciclovir NDA
Executive Summary
Scheduled July 13 meeting of FDA's Anti-Infective Drugs Advisory Cmte. postponed at agency's request to allow further review of Syntex NDA and analysis of Burroughs Wellcome data. B-W recently discontinued its IND for ganciclovir (for cytomegalovirus in immune-compromised patients), and Syntex assumed responsibility to provide the drug to former B-W patients under the Syntex IND and compassionate-use program. Discussion of the drug has not officially been rescheduled, but the committee's next meeting is Oct. 26-27.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.